Lates News

Insilico Medicine announcement: The Board of Directors of the Company is pleased to announce that, driven by Insilico Medicine's proprietary generative AI platform, the Company has nominated ISM1354 as a preclinical candidate compound, potentially for intervention in obesity, type 2 diabetes, and related diseases, and is expected to expand into the cardiovascular disease field.